» Articles » PMID: 18389894

Darunavir: Pharmacokinetics and Drug Interactions

Overview
Journal Antivir Ther
Publisher Sage Publications
Date 2008 Apr 9
PMID 18389894
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Darunavir (TMC114) is a new HIV protease inhibitor that has demonstrated substantial antiretroviral activity against wild-type HIV-1 virus and multidrug-resistant strains. Darunavir inhibits and is primarily metabolized by cytochrome P450 3A (CYP3A) isoenzymes and is coadministered with low-dose ritonavir (darunavir/r); ritonavir is an inhibitor of CYP3A isoenzymes and pharmacologically enhances darunavir, resulting in increased plasma concentrations and allowing for a lower daily dose. The t1/2 (terminal elimination half-life) of darunavir is 15 h in the presence of ritonavir. An extensive darunavir/r drug-drug interaction programme has been undertaken, covering a wide range of therapeutic areas. Studies conducted in HIV-negative healthy volunteers and in HIV-infected patients show that the potential for interactions is well characterized and the interactions are manageable. For most drugs investigated, no dose adjustments of darunavir/r or the co-administered drug are required. This article reviews all the pharmacokinetic and drug-drug interaction studies conducted to date for darunavir/r, providing guidance on how to co-administer darunavir/r with many other antiretroviral or non-antiretroviral medications commonly used in HIV-infected individuals.

Citing Articles

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.

Mia M, Howlader M, Akter F, Hossain M Clin Pathol. 2024; 17:2632010X241263054.

PMID: 39070952 PMC: 11282570. DOI: 10.1177/2632010X241263054.


A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form.

Biswal S, Mondal S, Mondal P J Pharm Bioallied Sci. 2021; 13(1):69-75.

PMID: 34084050 PMC: 8142922. DOI: 10.4103/jpbs.JPBS_337_19.


Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.

Marin R, Behl T, Negrut N, Bungau S Biomedicines. 2021; 9(3).

PMID: 33803812 PMC: 8003312. DOI: 10.3390/biomedicines9030313.


Drug repurposing approach to fight COVID-19.

Singh T, Parida S, Lingaraju M, Kesavan M, Kumar D, Singh R Pharmacol Rep. 2020; 72(6):1479-1508.

PMID: 32889701 PMC: 7474498. DOI: 10.1007/s43440-020-00155-6.


PERSIA for Direct Fluorescence Measurements of Transcription, Translation, and Enzyme Activity in Cell-Free Systems.

Wick S, Walsh 3rd D, Bobrow J, Hamad-Schifferli K, Kong D, Thorsen T ACS Synth Biol. 2019; 8(5):1010-1025.

PMID: 30920800 PMC: 6830305. DOI: 10.1021/acssynbio.8b00450.